B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma

  • STATUS
    Recruiting
  • days left to enroll
    89
  • participants needed
    3
  • sponsor
    Tongji University
Updated on 3 January 2022

Summary

This is an Open-label, Single Arm study to observe the safety and tolerability of B010-A in the treatment of advanced hepatocellular carcinoma.

Description

All subjects participating in this study will receive peripheral blood mononuclear cell collection to produce B010-A injection products after enrollment. Subjects may receive bridging anti-cancer therapy while waiting for the production of B010-A injection. All subjects need to undergo baseline assessment before receiving cell infusion. For all subjects, the baseline assessment includes weight, body surface area, vital signs, physical examination, ECOG score, laboratory examination, coagulation function, etiological examination, 12-lead ECG, echocardiogram, cytokine testing, Tumor marker detection and ICE score, etc. Each subject will receive lymphodepletion prior to B010-A infusion, and dose-limiting toxicity (DLT) assessment will be performed on D28 after the first infusion.

Details
Condition Advanced Hepatocellular Carcinoma
Treatment Biological/Vaccine: Low-dose group, Biological/Vaccine: Mid-dose group, Biological/Vaccine: High-dose group
Clinical Study IdentifierNCT05070156
SponsorTongji University
Last Modified on3 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

All subjects must meet all of the following criteria to be eligible for enrollment in this study
Aged 18-75 years, male or female
Subjects with histopathologically or cytologically confirmed advanced hepatocellular carcinoma (HCC) who are ineligible for surgery or local therapy, have progressed or being intolerant to prior standard systemic therapies (systemic therapies include but are not limited to systemic chemotherapy and molecular targeted therapy), or those who have no effective treatment options at the time of enrollment as judged by the investigator
Subjects with at least one stable and evaluable intrahepatic or extrahepatic target lesion (longest diameter of non-nodal lesions ≥ 10 mm, or short axis of lymph node lesions ≥ 15 mm) at enrollment as per RECIST V1.1 criteria
Subjects with GPC3 positive (> grade 2) tumor tissue samples (> 25% tumor cells positive staining) as tested by immunohistochemistry (IHC)
Subjects with Barcelona Clinic Liver Cancer Stage C (BCLC-C) hepatocellular carcinoma, or subjects with BCLC Stage B hepatocellular carcinoma who are not amenable to local therapy or have progressed after local therapy
Subjects with expected survival > 12 weeks
Subjects with liver cirrhosis of Child-Pugh grade A (5-6 points)
Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Subjects with inactive hepatitis B (if HBsAg or HBcAb is positive, then HBV-DNA must be < 20 IU/mL, and HBsAg-positive patients should have been treated with antiviral therapies as per the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition))
The largest diameter of intrahepatic tumors is < 10 cm, and the number of multiple tumors is < 10 (if pulmonary metastatic lesions are present, the number of metastatic lesions is < 6)
Subjects with a venous access for mononuclear cell collection
Subjects with adequate bone marrow function that allows for lympho-depleting pre-conditioning and without contraindications for the pre-conditioning as assessed by the investigator
Subjects with liver, kidney, respiratory, cardiovascular functions, and corresponding hematological levels as defined below
Alanine aminotransferase (ALT) ≤ 5.0 × ULN, aspartate aminotransferase (AST) ≤ 5.0 × ULN, and total bilirubin ≤ 2.5 × ULN at screening
Requirements for blood coagulation at screening: prothrombin time (PT) prolongation ≤ 4 s, fibrinogen ≥ 1 g/L, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN
Serum creatinine ≤ 1.5 × ULN or endogenous creatinine clearance > 50 mL/min (Cockcroft-Gault formula) at screening
Pulmonary function at screening: finger oxygen saturation ≥ 95% at screening and prior to apheresis
Cardiac function at screening: left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography within 1 month
Subjects with white blood cell count ≥ 3.0×109/L and lymphocyte count ≥ 0.5×109/L at screening (except for those receiving bridging chemotherapy), platelet count ≥ 75×109/L, hemoglobin ≥ 90 g/L, and neutrophil count ≥ 1.5×109/L (this criterion should also be met within 24 hours prior to apheresis)
Female subjects of childbearing potential (all women physiologically capable of
becoming pregnant) must have a negative serum pregnancy test both at screening
Subjects with ability to understand and sign the Informed Consent Form
and within 14 days prior to the first dose and are willing to use reliable
contraception methods during the study (within 24 months after the first dose
of cell infusion). For male subjects whose partners are women of childbearing
potential, the subjects should have been surgically sterilized or agree to use
reliable contraception methods during the study as well as for additional 1
year after receiving the last study treatment

Exclusion Criteria

Subjects who meet any of the following criteria cannot participate in this study
Having other uncured malignancies (except cervical carcinoma in situ and basal cell carcinoma of skin) within the past 5 years or at present, or hepatocellular carcinoma with brain metastases
With a history of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) Grade III or IV heart failure, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant heart diseases, or poorly controlled high blood pressure (systolic blood pressure > 150 mm Hg, or diastolic blood pressure > 90 mm Hg), or hypotension that requires treatment with vasopressors
With metastases to the central nervous system (CNS) and clinically significant CNS disorders; with prior or clinically significant CNS diseases at screening, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, brain organic syndrome or psychiatric disorder
With prior hepatic encephalopathy or at present
With a history of serious lung diseases, including pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease and clinically significant abnormal findings in pulmonary function tests
With known active autoimmune diseases requiring immunosuppressive therapy, including biologics
With a history of organ transplantation or awaiting organ transplantation (including liver transplantation)
With a co-infection of HBV and HCV viruses or infections caused by more than two viruses
Positive HCV-RNA, HIV antibody, or syphilis serology, or any other uncontrollable active infections
Requiring long-term antiplatelet therapy (aspirin > 300 mg/day; clopidogrel > 75 mg/day)
With an active infection (uncontrolled active infections caused by bacteria, viruses, or fungus requiring systemic therapy) at screening, or has an unexplained fever of ≥ 38.0 °C during screening or prior to the first dose
Have received prior cell-based therapies such as targeted GPC3 therapy, TCR-T therapy, CAR-T therapy
With moderate or higher amount of pleural effusion/ascites with clinical symptoms, or have undergone drainage of pleural effusion/ascites within the past month (except for those with only small amounts of pleural effusion/ascites revealed by imaging examinations but without symptoms)
With active bleeding or coagulation test abnormalities, bleeding tendency or undergoing thrombolytic, anticoagulant, or antiplatelet therapy (except those requiring heparin due to PICC or deep vein catheterization), or massive bleeding/blood loss (greater than 450 mL) within 28 days
With ≥ 50% of liver replaced by tumor, or with the main portal vein tumor thrombus, or the mesenteric vein/inferior vena cava has been invaded by tumor thrombus
With a history of gastrointestinal bleeding within 3 months or definite tendency of gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood positive)
Having received any of the following treatments
Have received supportive care such as blood transfusion, platelet transfusion, cell growth factors (except recombinant erythropoietin) within 2 weeks prior to apheresis
Have received anti-PD-1/PD-L1 monoclonal antibody treatment within 4 weeks prior to apheresis
Have used any study drug within 4 weeks prior to apheresis, except those who have failed to respond to the study treatment or have experienced disease progression during study treatment and at least 3 half-lives have passed prior to peripheral blood mononuclear cell collection)
Have undergone any surgical treatment, interventional therapy, chemoradiotherapy, ablation, targeted therapy, treatments with invasive investigational medical devices, or are receiving immunomodulatory therapy for the disease under study within 2 weeks prior to apheresis
Have received any Chinese herbal medicine or Chinese patent medicine to control liver cancer within 2 weeks prior to apheresis
Unable or unwilling to comply with protocol requirements as judged by the investigator
With prior use of prednisone at doses ≥ 15 mg /day (or equivalent glucocorticoids) systemically within 2 weeks prior to apheresis, or may require long-term glucocorticoid therapy during study treatment as judged by the investigator (except those who have recently or are currently using inhaled or topical glucocorticoids)
With previous allergic reactions to immunotherapy, have received related drugs
(such as tocilizumab, cyclophosphamide), or excipients or matrix components
contained in B010-A for Injection (e.g., albumin, dimethyl sulfoxide, etc.)
Toxicities caused by prior treatments have not recovered to CTCAE Grade ≤ 1, except for alopecia and other events judged as tolerable by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note